In VivoBiopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for
ScripThe latest third quarter data from the National Venture Capital Association (NVCA) and Pitchbook’s Venture Monitor report confirm recent data compiled by Evaluate Pharma, which showed that VC investme